Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial
J M Schattenberg, R Loomba, K V Kowdley, M Y Sheikh et autres
0 citationsZeitschrift für Gastroenterologie